Anatara Lifesciences Ltd
ASX: ANR.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Lionel Brookes
- Employees
- 7
- Headquarters
- Adelaide, Australia
- IPO year
- 2014
- Market cap
- A$1.9M
- Website
- https://anataralifesciences.com
Loading ANR…
Loading profile data…Frequently asked questions about ANR
What does Anatara Lifesciences Ltd (ANR.AX) do?
Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying fa...
Where does ANR.AX trade?
Anatara Lifesciences Ltd (ANR.AX) trades on the Australian Securities Exchange.
What sector is ANR.AX in?
Anatara Lifesciences Ltd (ANR.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Anatara Lifesciences Ltd?
David Lionel Brookes is the chief executive officer of Anatara Lifesciences Ltd (ANR.AX).
Where is Anatara Lifesciences Ltd headquartered?
Anatara Lifesciences Ltd is headquartered in Australia.
Does ANR.AX pay a dividend?
Anatara Lifesciences Ltd (ANR.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ANR.AX go public?
Anatara Lifesciences Ltd (ANR.AX) completed its initial public offering in 2014.